IMITREX injection drug interactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Sumatriptan}} {{CMG}}; {{AE}} {{SS}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = IMITREX (SUMATRIPTAN SUCCINATE) INJECTION [GLAX...")
 
No edit summary
 
(3 intermediate revisions by one other user not shown)
Line 3: Line 3:
{{CMG}}; {{AE}} {{SS}}
{{CMG}}; {{AE}} {{SS}}


==Drug Interactions==


====Ergot-Containing Drugs====


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = IMITREX (SUMATRIPTAN SUCCINATE) INJECTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fee7d073-0b99-48f2-7985-0d8cf970894b | publisher =  | date =  | accessdate = }}</ref>
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of [[ergotamine]]-containing or ergot-type medications (like [[dihydroergotamine]] or [[methysergide]]) and IMITREX Injection within 24 hours of each other is contraindicated.


====Monoamine Oxidase-A Inhibitors====


MAO-A inhibitors increase systemic exposure by 2-fold. Therefore, the use of IMITREX Injection in patients receiving MAO-A inhibitors is contraindicated [see Clinical Pharmacology (12.3)].
====Other 5-HT1 Agonists====
Because their vasospastic effects may be additive, coadministration of IMITREX Injection and other 5-HT<sub>1</sub> agonists (e.g., [[triptans]]) within 24 hours of each other is contraindicated.
====Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome====
Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, or SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)].<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = IMITREX (SUMATRIPTAN SUCCINATE) INJECTION [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=fee7d073-0b99-48f2-7985-0d8cf970894b | publisher =  | date =  | accessdate = }}</ref>


==References==
==References==

Latest revision as of 22:14, 19 February 2014

Sumatriptan
IMITREX injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
IMITREX tablet® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
IMITREX spray® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Sumatriptan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Drug Interactions

Ergot-Containing Drugs

Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and IMITREX Injection within 24 hours of each other is contraindicated.

Monoamine Oxidase-A Inhibitors

MAO-A inhibitors increase systemic exposure by 2-fold. Therefore, the use of IMITREX Injection in patients receiving MAO-A inhibitors is contraindicated [see Clinical Pharmacology (12.3)].

Other 5-HT1 Agonists

Because their vasospastic effects may be additive, coadministration of IMITREX Injection and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated.

Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome

Cases of serotonin syndrome have been reported during coadministration of triptans and SSRIs, or SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)].[1]

References

  1. "IMITREX (SUMATRIPTAN SUCCINATE) INJECTION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.